吡咯替尼对SNU-1胃癌细胞增殖能力及不同类型胃癌组织中钙黏蛋白S100A10表达的影响  

Effect of pyrrolotinib on proliferation of SNU-1 gastric cancer cells and expression of cadherin S100A10 in different types of gastric cancer tissues

作　　者：王兴国[1] 贾娇 马林[3] WANG Xingguo;JIA Jiao;MA Lin(Department of General Surgery,Yulin No.2 Hospital,Yulin 719000,China)

机构地区：[1]榆林市第二医院普通外科,陕西榆林719000 [2]榆林市第二医院消化内科,陕西榆林719000 [3]宝鸡市中医医院普通外科,陕西宝鸡721000

出　　处：《陕西医学杂志》2021年第8期917-920,944,共5页Shaanxi Medical Journal

基　　金：陕西省科技厅科研基金资助项目(2018231)。

摘　　要：目的:探讨吡咯替尼对SNU-1胃癌细胞增殖能力及不同类型胃癌组织中钙黏蛋白S100A10表达的影响。方法:分别以不同浓度的吡咯替尼作用于SNU-1胃癌细胞株,检测不同浓度吡咯替尼对SNU-1胃癌细胞株的影响;提取不同类型的胃癌组织进行免疫组化染色,检测钙黏蛋白S100A10在不同组织中的表达情况;并选取高分化腺癌、中分化腺癌、低分化腺癌、淋巴结转移癌每种20个存活组织,应用100μmol/ml浓度吡咯替尼分别加入到不同类型的胃癌组织中干预48 h,应用免疫组织化学法测定组织中钙黏蛋白S100A10表达情况。结果:①不同浓度吡咯替尼对SNU-1胃癌细胞在24、36、48 h的生长抑制作用逐渐增强,组间对比差异具有统计学意义(均P<0.01);②免疫组化染色结果显示S100A10蛋白主要位于细胞浆内,且表达情况也有所不同;正常胃黏膜中S100A10蛋白表阳性表达率为5.00%,非典型增生组织为20.00%,高分化腺癌为40.00%,中分化腺癌为55.00%,低分化腺癌为65.00%,淋巴结转移为65.00%,组间对比差异有统计学意义(均P<0.05);③吡咯替尼干预前后中分化腺癌和低分化腺癌组织中S100A10阳性率影响对比差异有统计学意义(均P<0.05)。结论:吡咯替尼对人胃癌细胞增殖能力具有抑制作用,不同类型胃癌组织中钙黏蛋白S100A10表达有所不同,随着胃癌细胞的增殖,钙黏蛋白S100A10表达的阳性表达增高,吡咯替尼对于不同类型胃癌组织钙黏蛋白S100A10表达具有一定影响,推测吡咯替尼对胃癌可能具有一定治疗作用,可为胃癌的临床治疗提供参考。Objective:To investigate the effect of pyrrolotinib on proliferation of SNU-1 gastric cancer cells and expression of cadherin S100A10 in different types of gastric cancer tissues.Methods:SNU-1 gastric cancer cell lines were treated with different concentrations of pyrrolotinib.The effects of different concentrations of pyrrolotinib on SNU-1 gastric cancer cell lines were detected.Different gastric tissues were extracted for immunohistochemical staining.The expression of cadherin S100A10 in different tissues was detected.Twenty survival tissues of each type(well differentiated adenocarcinoma,moderately differentiated adenocarcinoma,poorly differentiated adenocarcinoma,and lymph node metastasis)were used,and 100μmol/ml concentration of pyrrotinib was applied to different types of gastric cancer tissues.After 48 hours of intervention,the expression of cadherin S100A10 in different gastric cancer tissues was detected by immunohistochemistry.Results:Different concentrations of pyrrolotinib enhanced the growth inhibition of SNU-1 gastric cancer cells at 24,36,48 hours(all P<0.01).Immunohistochemical staining showed that S100A10 protein was mainly located in the cytoplasm,and the expression was also different.The positive expression rate of S100A10 protein in normal gastric mucosa was 5.00%,atypical hyperplasia tissue was 20.00%,well differentiated adenocarcinoma was 40.00%,moderately differentiated adenocarcinoma was 55.00%,poorly differentiated adenocarcinoma was 65.00%,and lymph node metastasis was 65.00%,the difference between the groups was statistically significant(all P<0.05).There was significant difference in S100A10 positive rate between moderately differentiated adenocarcinoma and poorly differentiated adenocarcinoma before and after pyrrolitinib intervention(all P<0.05).Conclusion:Pyrrolotinib has inhibitory effect on the proliferation of human gastric cancer cells.The expression of cadherin S100A10 in different gastric tissues is different.With the proliferation of gastric cancer cells,the expression of ca

关 键 词：吡咯替尼 胃癌细胞 胃组织 钙黏蛋白S100A10 增殖能力 抑制率 分化程度 

分 类 号：R735.2[医药卫生—肿瘤]